Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Brainstorm Cell Therapeutics ( (BCLI) ) has provided an announcement.
On December 31, 2025, and January 5 and 6, 2026, Brainstorm Cell Therapeutics Inc. entered into three unsecured securities purchase transactions with institutional investors, issuing promissory and convertible promissory notes with original issue discounts and one-time interest charges, in aggregate principal amounts of $94,300, $94,875 and $140,000, respectively. The financings, which were conducted as private placements exempt from SEC registration, provided the company with short- to medium-term funding through discounted debt that may convert into equity at variable prices upon events of default or after specified holding periods, introducing potential future equity dilution while strengthening near-term liquidity and embedding investor protections such as default premiums, ownership caps, cross-defaults, and repayment rights tied to future financings.
The most recent analyst rating on (BCLI) stock is a Hold with a $0.58 price target. To see the full list of analyst forecasts on Brainstorm Cell Therapeutics stock, see the BCLI Stock Forecast page.
Spark’s Take on BCLI Stock
According to Spark, TipRanks’ AI Analyst, BCLI is a Neutral.
Overall score is held down mainly by weak financial performance (large operating losses, ongoing cash burn, and equity/funding risk). Technicals are also soft with the stock below key longer-term averages. Corporate events add some support via new financing and development progress, but carry dilution/financing risk, and valuation remains constrained by negative earnings and no dividend.
To see Spark’s full report on BCLI stock, click here.
More about Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc. is a biotechnology company focused on developing cell-based therapies, operating in the life sciences sector and relying on capital markets and structured financings to fund its research, development and corporate activities.
Average Trading Volume: 21,698
Technical Sentiment Signal: Sell
Current Market Cap: $6.07M
For an in-depth examination of BCLI stock, go to TipRanks’ Overview page.